enVVeno Medical Business Summary

enVVeno Medical Corp (NVNO) is a late clinical-stage medical device company that generates revenue through the future commercialization and product sales of bioprosthetic tissue-based solutions for chronic venous insufficiency (CVI). The company operates in a single business segment focused on the development of its flagship products: the VenoValve, a first-in-class surgical replacement venous valve, and enVVe, a non-surgical transcatheter-based replacement system. Currently pre-revenue, enVVeno’s business model is predicated on securing FDA Premarket Approval (PMA) to address a multi-billion dollar unmet market of 2.5 million U.S. patients suffering from deep venous disease. While the company faces direct clinical competition from vascular giants such as Medtronic, Boston Scientific, and Edwards Lifesciences, it maintains a unique market position as the only firm currently pursuing a Breakthrough Device-designated replacement venous valve, though it is currently navigating regulatory hurdles following an unfavorable FDA appeal decision in late 2025. Originally founded in 1999 as Hancock Jaffe Laboratories by Norman Jaffe and Robert Hancock, the company rebranded to enVVeno in 2021 to align with its singular focus on venous health. The leadership team is led by CEO Robert Berman, who joined in 2018 with over 25 years of experience in healthcare turnarounds and technology licensing, previously serving as CEO of ITUS Corporation. He is supported by SVP and CTO Hamed Alavi, Ph.D., a former engineering lead at Medtronic and Edwards Lifesciences, and CFO Jennifer Bright, who brought 25 years of financial pedigree from Teleflex and Biolase upon joining in 2025. The company’s Board of Directors includes high-profile industry veterans such as Dr. Francis Duhay, former CMO of Edwards Lifesciences, and Dr. Sanjay Shrivastava, formerly of Abbott Vascular. Notable institutional backing is provided by Perceptive Advisors LLC, Kingdon Capital Management, and the Vanguard Group, reflecting significant professional interest in the company’s specialized bioprosthetic pipeline.